Clinical studies have shown poor prognoses for patients with most subtypes of peripheral T-cell lymphoma (PTCL), especially for those who have received conventional chemotherapy, as well as high relapse and low overall survival rates, but doctors said a new antifolate could be an effective alternative to traditional treatments.
Chang Ming-chih (張明志), consultant hematologist and oncologist at Mackay Memorial Hospital, said an average of about 330 PTCL cases were reported in Taiwan each year in the past few years and the numbers appear to be growing, adding that there are many different types of PTCL and most of them are aggressive.
Chang said that a study conducted overseas in 2013 showed that the three-year survival rate of PTCL patients after their first relapse was only 18 percent, adding that survival rates can be increased significantly for those who receive hematopoietic stem cell transplantations (HSCT).
Photo: Ruby Chang
However, patients are sometimes too weak to undergo HSCT due to age or the side effects of conventional chemotherapy, or they are unwilling to accept treatment due the to high relapse rate, he said, adding that the average lifespan of PTCL patients after their first relapse or progression is about five-and-a-half months without HSCT.
Chang said that a new antifolate — Pralatrexate — has been proven to extend the duration of a response from therapy, which means it might give patients the chance to undergo HSCT and increase their survival rate.
Speaking in Taipei last weekend, Owen A. O’Connor, a professor of medicine and experimental therapeutics and the director of the Center for Lymphoid Malignancies at Columbia University Medical Center, said that the antifolate works by mimicking folic acids to selectively enter cells expressing RFC-1, a protein that is expressed in certain cancer cells but seldom in normal cells.
Once inside cancer cells, the Pralatrexate acts on the folate pathway, interfering with DNA synthesis and suppressing the growth of the cancer cell, he said.
A clinical study conducted on more than 100 adult patients with relapsed or refractory PTCL showed that the average response rate to the new drug was 29 percent and the average duration of response was 12 months, O’Connor said.
In most parts of the world, the typical frontline treatment for PTCL is a combination of chemotherapy commonly known as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), but only up to 20 percent of the patients that undergo CHOP are expected to be cured, he said.
The most common solution for treating patients who did not respond to CHOP is to give them more chemotherapy, but for patients with T-cell lymphoma, cancer cells become resistant to many types of chemotherapy, O’Conner said, adding: “So we need new drugs that work in a different mechanism from traditional chemotherapy.”
“It is important for doctors and patients alike to recognize that chemotherapy might not always be the answer, and to think about how to use new drugs as a bridge to curative therapy like transplantation or a strategy to manage the disease for long periods of time,” he said, adding that Pralatrexate has exhibited marked and durable activity in heavily treated patients across all subtypes of PTCL.
Chang said that lymphoma might develop in many parts of the body and there are many types and subtypes of the disease, so sometimes patients and physicians might have difficulty diagnosing it.
He advised people to see a doctor if they have the following symptoms: swelling in the whole body or in the neck or the armpits; painless lymph node enlargement; high fever for more than two weeks; night sweats; loss of 3 to 5 percent or more of body weight within six months; fatigue or nasal congestion (similar to sinusitis, but with bleeding).
SECURITY: Starlink owner Elon Musk has taken pro-Beijing positions, and allowing pro-China companies to control Taiwan’s critical infrastructure is risky, a legislator said Starlink was reluctant to offer services in Taiwan because of the nation’s extremely high penetration rates in 4G and 5G services, the Ministry of Digital Affairs said yesterday. The ministry made the comments at a meeting of the legislature’s Transportation Committee, which reviewed amendments to Article 36 of the Telecommunications Management Act (電信管理法). Article 36 bans foreigners from holding more than 49 percent of shares in public telecommunications networks, while shares foreigners directly and indirectly hold are also capped at 60 percent of the total, unless specified otherwise by law. The amendments, sponsored by Chinese Nationalist Party (KMT) Legislator Ko
The eastern extension of the Taipei MRT Red Line could begin operations as early as late June, the Taipei Department of Rapid Transit Systems said yesterday. Taipei Rapid Transit Corp said it is considering offering one month of free rides on the new section to mark its opening. Construction progress on the 1.4km extension, which is to run from the current terminal Xiangshan Station to a new eastern terminal, Guangci/Fengtian Temple Station, was 90.6 percent complete by the end of last month, the department said in a report to the Taipei City Council's Transportation Committee. While construction began in October 2016 with an
The military has spotted two Chinese warships operating in waters near Penghu County in the Taiwan Strait and sent its own naval and air forces to monitor the vessels, the Ministry of National Defense (MND) said. Beijing sends warships and warplanes into the waters and skies around Taiwan on an almost daily basis, drawing condemnation from Taipei. While the ministry offers daily updates on the locations of Chinese military aircraft, it only rarely gives details of where Chinese warships are operating, generally only when it detects aircraft carriers, as happened last week. A Chinese destroyer and a frigate entered waters to the southwest
NON-RED SUPPLY: Boosting the nation’s drone industry is becoming increasingly urgent as China’s UAV dominance could become an issue in a crisis, an analyst said Taiwan’s drone exports to Europe grew 41.7-fold from 2024 to last year, with demand from Ukraine’s fight against Russian aggression the most likely driver of growth, a study showed. The Institute for Democracy, Society and Emerging Technology (DSET) in a statement on Wednesday said it found that many of Taiwan’s uncrewed aerial vehicle (UAV) sales were from Poland and the Czech Republic. These countries likely transferred the drones to Ukraine to aid it in its fight against the Russian invasion that started in 2022, it said. Despite the gains, Taiwan is not the dominant drone exporter to these markets, ranking second and fourth
RSS